Clinical Trials Logo

Small Bowel Cancer clinical trials

View clinical trials related to Small Bowel Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04526886 Completed - Colorectal Cancer Clinical Trials

Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy

Start date: October 15, 2020
Phase: N/A
Study type: Interventional

The study is testing an intervention of an investigator-developed chemotherapy dose adjustment algorithm. The primary objective of this study is to evaluate the effectiveness of the chemotherapy dose adjustment algorithm for reducing unplanned delays in patients receiving FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)-type chemotherapy, while maintaining acceptable chemotherapy dose-intensity.

NCT ID: NCT04316078 Completed - Gastric Cancer Clinical Trials

A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies

Start date: March 15, 2020
Phase: N/A
Study type: Interventional

A randomized control trial to evaluate the feasibility of implementing a patient educational platform (PEP) for patients with gastrointestinal malignancies undergoing active chemotherapy treatment.

NCT ID: NCT00831571 Completed - Colorectal Cancer Clinical Trials

Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin

Start date: February 2009
Phase:
Study type: Observational

This research study will examine how often hypersensitivity, or allergic reactions, occur in patients receiving the chemotherapy medication oxaliplatin. Hypersensitivity reactions can vary from a transient skin rash and fever to more severe symptoms such as shortness of breath, chest tightness, and a more severe allergic reaction that can affect blood pressure called anaphylaxis. We will be examining how often hypersensitivity reactions occur and how severe the reactions are when they occur. We will also examine whether there are factors that place people at risk for developing hypersensitivity reactions to oxaliplatin. In an optional portion to this study, we will examine whether allergy skin testing can predict whether someone will develop a hypersensitivity reaction. Participants who develop a moderate to severe allergic reaction to oxaliplatin will be invited to participate in an additional portion of the study examining a desensitization process. This part of the study will examine whether a desensitization process can prevent future hypersensitivity reactions to oxaliplatin in patients who previously developed moderate to severe hypersensitivity reactions and allow therapy with oxaliplatin to continue.